These studies resulted in the approval of trastuzumab in HER2-expressing G/GEJ cancers and the use of trastuzumab with pertuzumab in HER2-amplified/RAS-BRAF wild-type colorectal cancer (CRC) [21,22,23]. Here, ERBB2 is linked to colorectal carcinoma.